The UNITED STATES
Moderna: US biotech firm Moderna has clearly stated that it will not be ready to apply for emergency authorisation for its COVID-19 vaccine before the US presidential election.
Pfizer: Another US vaccine developer, Pfizer and its partner BioNTech have said the companies expect phase 3 data by the end of October.
Novavax: The US-based biotech company will enroll 10,000 participants aged 18 to 84 within the next four to six weeks, with 25 per cent being over 65. Novavax is making a vaccine that consists of two shots given 21 days apart
Johnson & Johnson: Another US-based frontrunner of COVID-19 vaccine J&J released an interim analysis from the ongoing phase 1/2 clinical trial of its candidate. The company said, "strong neutralising antibody response in nearly all participants were observed".